This is crucial for identifying the 10% of astrocytomas with noncanonical IDH mutations undetectedable using IDH R132H immunohistochemistry and for recognizing astrocytomas with molecular characteristics resembling glioblastoma (Whitfield and Huse, 2022). This evidence concerns the gene IDH1 and glioblastoma.